RxDoctor Payments Data

Shelbi Navarrette, APRN

Nurse Practitioner · Elizabethtown, KYNPI 1285178517

Payments from drug & device makers

$4,411in general payments, 2019–2025

Across 244 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$998
  • AbbVie$778
  • AstraZeneca$703
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$356
  • Lilly USA, LLC$274
  • Pfizer$209
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$4,411100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,411 in reported general payments places this provider in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$31,126
Medicare patients
94
Services billed
844

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$89,096
JardianceEmpagliflozin48$48,117
FarxigaDapagliflozin Propanediol34$34,651
RybelsusSemaglutide19$34,357
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$23,245
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$13,498
TradjentaLinagliptin12$5,663
Albuterol Sulfate HfaAlbuterol Sulfate128$4,787
Ventolin HfaAlbuterol Sulfate30$2,316
Levothyroxine Sodium146$2,246
Celecoxib43$2,097
Bupropion XlBupropion Hcl79$1,816
Pilocarpine Hcl19$1,781
Gabapentin116$1,707
Pregabalin11$1,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$998$123,45292 claims
Boehringer IngelheimJardiance, Tradjenta$49$53,78160 claims
AstraZenecaFarxiga, Breztri Aerosphere$703$48,14947 claims
GSKTrelegy Ellipta$162$23,24520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Elizabethtown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →